ArticleActa pharmaceutica Sinica. B2017
Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21
Open access · diamondAbstract read
In one paragraph
Article in Acta pharmaceutica Sinica. B, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 42 citations in OpenAlex.
- Epigenetic modifications in cancer drug resistance: molecular mechanisms and therapeutic interventions.Molecular biomedicine · 2026Review
- Potential role of hypobaric hypoxia environment in treating pan-cancer.Scientific reports · 2025Article
- Recent Issues in the Development and Application of Targeted Therapies with Respect to Individual Animal Variability.Animals : an open access journal from MDPI · 2025Review
- GLP-1RAs attenuated obesity and reversed leptin resistance partlyActa pharmaceutica Sinica. B · 2025Article
- The 2024 Nobel Prize in Physiology or Medicine: microRNA Takes Center Stage.Non-coding RNA · 2024Article
- The regulatory role of antisense lncRNAs in cancer.Cancer cell international · 2021Review
- Downregulation of lncRNA ZNF582-AS1 due to DNA hypermethylation promotes clear cell renal cell carcinoma growth and metastasis by regulating the N(6)-methyladenosine modification of MT-RNR1.Journal of experimental & clinical cancer research : CR · 2021Article
- INTEDE: interactome of drug-metabolizing enzymes.Nucleic acids research · 2021Article
- A cluster of long non-coding RNAs exhibit diagnostic and prognostic values in renal cell carcinoma.Aging · 2019Article
- Current trends in drug metabolism and pharmacokinetics.Acta pharmaceutica Sinica. B · 2019Review
- Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters.Acta pharmaceutica Sinica. B · 2019Article
- Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and dispositionActa pharmaceutica Sinica. B · 2019Article
- The HNF1The Journal of pharmacology and experimental therapeutics · 2019Article
- Plateau hypoxia attenuates the metabolic activity of intestinal flora to enhance the bioavailability of nifedipine.Drug delivery · 2018Article
- Arenobufagin is a novel isoform-specific probe for sensing human sulfotransferase 2A1.Acta pharmaceutica Sinica. B · 2018Article
- Nuclear Receptor SHP: A Critical Regulator of miRNA and lncRNA Expression and Function.Nuclear receptor research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 13 institutions in 3 countries.
Ai-Ming YuDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California at Davis, Sacramento, CA 95817, USA.
Magnus Ingelman-SundbergDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Nathan J CherringtonDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA.
Lauren M AleksunesDepartment of Pharmacology and Toxicology, School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA.
Ulrich M ZangerDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany; Eberhard Karls University, Tuebingen, Germany.
Wen XieCenter of Pharmacogenomics and Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Hyunyoung JeongDepartment of Pharmacy Practice, School of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA.
Edward T MorganDepartment of Pharmacology, School of Medicine, Emory University, Atlanta, GA 30322, USA.
Peter J TurnbaughDepartment of Microbiology and Immunology and the George William Hooper Research Foundation, University of California at San Francisco, San Francisco, CA 94143, USA.
Curtis D KlaassenDepartment of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA 98195, USA.
Aadra P BhattDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Matthew R RedinboDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Pengying HaoDepartment of Biology and Bioinformatics Program, Boston University, Boston, MA 02215, USA.
David J WaxmanDepartment of Biology and Bioinformatics Program, Boston University, Boston, MA 02215, USA.
Li WangDepartment of Physiology and Neurobiology, University of Connecticut, Storrs, CT 06269, USA.
Xiao-Bo ZhongDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA.
Boston University · USUniversity of Connecticut · USUniversity of North Carolina at Chapel Hill · USEmory University · USKarolinska Institutet · SERutgers, The State University of New Jersey · USSan Francisco Foundation · USUniversity of Arizona · USUniversity of California, Davis · USUniversity of Illinois Chicago · USUniversity of Pittsburgh · USUniversity of Tübingen · DEUniversity of Washington · US
Funding
Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI PANOS G. GEORGOPOULOS · 1988 to 2026
$47.4MSOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · NIEHS · UNIVERSITY OF ARIZONA · PI DEAN BILLHEIMER · 1994 to 2026
$36.7MUNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3MYale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI YASUKO IWAKIRI · 1986 to 2026
$31.1MTraining in Environmental Toxicology of Human DiseaseT32ES007091 · NIEHS · UNIVERSITY OF ARIZONA · PI Nathan J Cherrington · 1985 to 2026
$10.7MRegulation of Sex Differences in Liver MetabolismR01DK033765 · NIDDK · DANA-FARBER CANCER INSTITUTE · PI WAXMAN, DAVID J · 1986 to 2017
$8.7MGASTROENTEROLOGY RESEARCH TRAININGT32DK007737 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SHEHZAD Z. SHEIKH · 1996 to 2026
$7.8MPredicting and preventing drug metabolism by the human gut microbiomeR01HL122593 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Peter James Turnbaugh · 2016 to 2026
$5.7MXenobiotic-responsive hepatic long non-coding RNAsR01ES024421 · NIEHS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI WAXMAN, DAVID J · 2014 to 2024
$4.6MImproving CPT-11 Efficacy Using Structural BiologyR01CA098468 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI REDINBO, MATTHEW R · 2003 to 2018
$3.9MDevelopmental Regulation of Drug Processing GenesR01ES019487 · NIEHS · UNIVERSITY OF WASHINGTON · PI CUI, JULIA YUE, LU, HONG · 2010 to 2014
$3.0MThe AHR-FGF221 Axis in Hepatic Steatosis and Metobolic SyndromeR01DK083952 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI XIE, WEN · 2010 to 2019
$3.0MBLRD VA I01 BX002634NCI NIH HHS R01 CA098468NCI NIH HHS U01 CA175315NHLBI NIH HHS R01 HL122593NIAAA NIH HHS R21 AA022482NIAAA NIH HHS R21 AA024935NIDDK NIH HHS P30 DK034989NIDDK NIH HHS R01 DK033765NIDDK NIH HHS R01 DK080440NIDDK NIH HHS R01 DK083952NIDDK NIH HHS R01 DK104656NIDDK NIH HHS T32 DK007737NIEHS NIH HHS P30 ES005022NIEHS NIH HHS P30 ES006694NIEHS NIH HHS P30 ES010126NIEHS NIH HHS R01 ES019487NIEHS NIH HHS R01 ES020522NIEHS NIH HHS R01 ES021800NIEHS NIH HHS R01 ES023438NIEHS NIH HHS R01 ES024421NIEHS NIH HHS R01 ES025708NIEHS NIH HHS R01 ES025909NIEHS NIH HHS T32 ES007091NIGMS NIH HHS R01 GM087376NIGMS NIH HHS R01 GM113888NIGMS NIH HHS R01 GM118367
Abstract
Variations in drug metabolism may alter drug efficacy and cause toxicity; better understanding of the mechanisms and risks shall help to practice precision medicine. At the 21
Indexed as
DiseaseDrug metabolism and toxicityEpigeneticsGeneticsGut microbiotaLong non-coding RNAsPersonalized medication
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.